At Minoryx, we are committed to finding novel treatments for life threatening rare diseases. We prioritize pediatric diseases and we are currently focused on neurometabolic diseases of genetic origin. Minoryx develops a new generation of small molecule drugs named pharmacological chaperones, which are the most promising approach to treat genetic diseases affecting the central nervous system. As a complementary approach, Minoryx also progress repositioning-based projects